Cargando…

Development and validation of a high throughput whole blood thrombolysis plate assay

The objective of this work was to develop a high throughput assay for testing in vitro the thrombolytic activity using citrated whole blood samples, and to overcome the limitations of currently available techniques. We successfully developed a method that involves forming halo shaped, tissue factor...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnard, T., Law, L. S., Tennant, Z., Hagemeyer, C. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443825/
https://www.ncbi.nlm.nih.gov/pubmed/28539608
http://dx.doi.org/10.1038/s41598-017-02498-2
_version_ 1783238627803791360
author Bonnard, T.
Law, L. S.
Tennant, Z.
Hagemeyer, C. E.
author_facet Bonnard, T.
Law, L. S.
Tennant, Z.
Hagemeyer, C. E.
author_sort Bonnard, T.
collection PubMed
description The objective of this work was to develop a high throughput assay for testing in vitro the thrombolytic activity using citrated whole blood samples, and to overcome the limitations of currently available techniques. We successfully developed a method that involves forming halo shaped, tissue factor induced, whole blood clots in 96 well plates, and then precisely measuring the thrombolysis process with a spectrophotometer plate reader. We here describe the implementation of this novel method, which we refer to as halo assay, and its validation with plasmin, urokinase and tissue plasminogen activator at different doses. The resulting data is a highly detailed thrombolysis profile, allowing comparison of different fibrinolytic agents. The time point analysis allows kinetic data to be collected and calculated to determine key parameters such as the activation time and the rate of fibrinolysis. We also assessed the capacity of the model to study the effect of clot maturation time on the fibrinolytic rate, an aspect of thrombosis rather unexplored with currently available methods, but of increasing importance in drug development. This novel thrombolysis assay could be an extremely useful research tool; to study the complex process of thrombolysis, and a valuable translational clinical tool; as a screening device to rapidly identify hypo- or hyper-fibrinolysis.
format Online
Article
Text
id pubmed-5443825
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54438252017-05-26 Development and validation of a high throughput whole blood thrombolysis plate assay Bonnard, T. Law, L. S. Tennant, Z. Hagemeyer, C. E. Sci Rep Article The objective of this work was to develop a high throughput assay for testing in vitro the thrombolytic activity using citrated whole blood samples, and to overcome the limitations of currently available techniques. We successfully developed a method that involves forming halo shaped, tissue factor induced, whole blood clots in 96 well plates, and then precisely measuring the thrombolysis process with a spectrophotometer plate reader. We here describe the implementation of this novel method, which we refer to as halo assay, and its validation with plasmin, urokinase and tissue plasminogen activator at different doses. The resulting data is a highly detailed thrombolysis profile, allowing comparison of different fibrinolytic agents. The time point analysis allows kinetic data to be collected and calculated to determine key parameters such as the activation time and the rate of fibrinolysis. We also assessed the capacity of the model to study the effect of clot maturation time on the fibrinolytic rate, an aspect of thrombosis rather unexplored with currently available methods, but of increasing importance in drug development. This novel thrombolysis assay could be an extremely useful research tool; to study the complex process of thrombolysis, and a valuable translational clinical tool; as a screening device to rapidly identify hypo- or hyper-fibrinolysis. Nature Publishing Group UK 2017-05-24 /pmc/articles/PMC5443825/ /pubmed/28539608 http://dx.doi.org/10.1038/s41598-017-02498-2 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Bonnard, T.
Law, L. S.
Tennant, Z.
Hagemeyer, C. E.
Development and validation of a high throughput whole blood thrombolysis plate assay
title Development and validation of a high throughput whole blood thrombolysis plate assay
title_full Development and validation of a high throughput whole blood thrombolysis plate assay
title_fullStr Development and validation of a high throughput whole blood thrombolysis plate assay
title_full_unstemmed Development and validation of a high throughput whole blood thrombolysis plate assay
title_short Development and validation of a high throughput whole blood thrombolysis plate assay
title_sort development and validation of a high throughput whole blood thrombolysis plate assay
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443825/
https://www.ncbi.nlm.nih.gov/pubmed/28539608
http://dx.doi.org/10.1038/s41598-017-02498-2
work_keys_str_mv AT bonnardt developmentandvalidationofahighthroughputwholebloodthrombolysisplateassay
AT lawls developmentandvalidationofahighthroughputwholebloodthrombolysisplateassay
AT tennantz developmentandvalidationofahighthroughputwholebloodthrombolysisplateassay
AT hagemeyerce developmentandvalidationofahighthroughputwholebloodthrombolysisplateassay